C WorldWide Group Holding A S Increases Position in ResMed Inc. (NYSE:RMD)

C WorldWide Group Holding A S increased its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 37.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,309 shares of the medical equipment provider's stock after buying an additional 26,528 shares during the quarter. C WorldWide Group Holding A S owned about 0.07% of ResMed worth $16,911,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RMD. EverSource Wealth Advisors LLC lifted its stake in ResMed by 224.6% during the third quarter. EverSource Wealth Advisors LLC now owns 185 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 128 shares during the last quarter. Operose Advisors LLC bought a new position in shares of ResMed in the 3rd quarter valued at $32,000. Planned Solutions Inc. bought a new position in shares of ResMed in the 4th quarter valued at $34,000. MV Capital Management Inc. lifted its stake in shares of ResMed by 39.0% in the 4th quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 60 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new position in shares of ResMed in the 4th quarter valued at $45,000. Institutional investors and hedge funds own 54.98% of the company's stock.

Insider Activity

In other news, Director Peter C. Farrell sold 10,935 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now directly owns 157,404 shares in the company, valued at approximately $28,751,414.64. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Peter C. Farrell sold 10,935 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now directly owns 157,404 shares in the company, valued at approximately $28,751,414.64. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Michael J. Rider sold 200 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the completion of the transaction, the general counsel now directly owns 6,688 shares in the company, valued at approximately $1,158,696. The disclosure for this sale can be found here. Insiders sold a total of 11,216 shares of company stock worth $2,046,617 in the last three months. Company insiders own 1.21% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on RMD. JPMorgan Chase & Co. increased their price target on ResMed from $160.00 to $195.00 and gave the company an "overweight" rating in a research note on Tuesday, January 9th. KeyCorp increased their price objective on ResMed from $227.00 to $238.00 and gave the company an "overweight" rating in a report on Friday. UBS Group increased their price objective on ResMed from $175.00 to $180.00 and gave the company a "neutral" rating in a report on Thursday, January 25th. Royal Bank of Canada increased their price objective on ResMed from $187.00 to $200.00 and gave the company a "sector perform" rating in a report on Friday. Finally, Mizuho restated a "buy" rating and issued a $215.00 price objective on shares of ResMed in a report on Wednesday, March 27th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, ResMed presently has an average rating of "Moderate Buy" and an average price target of $202.80.

ResMed Stock Up 18.9 %

Shares of RMD traded up $34.64 during trading hours on Friday, hitting $218.06. The stock had a trading volume of 4,330,840 shares, compared to its average volume of 1,052,924. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.11 and a quick ratio of 1.89. The firm has a 50 day simple moving average of $187.07 and a 200-day simple moving average of $172.12. The firm has a market capitalization of $32.07 billion, a P/E ratio of 33.50, a price-to-earnings-growth ratio of 2.26 and a beta of 0.67. ResMed Inc. has a 1-year low of $132.24 and a 1-year high of $243.52.

ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 EPS for the quarter, beating the consensus estimate of $1.91 by $0.22. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. ResMed had a return on equity of 24.92% and a net margin of 20.91%. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the business posted $1.68 EPS. Sell-side analysts predict that ResMed Inc. will post 7.44 EPS for the current fiscal year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Thursday, May 9th will be paid a $0.48 dividend. The ex-dividend date is Wednesday, May 8th. This represents a $1.92 annualized dividend and a dividend yield of 0.88%. ResMed's dividend payout ratio is presently 29.49%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.